These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 11391689

  • 1. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.
    Goldman AI, Hannan PJ.
    Stat Med; 2001 Jun 15; 20(11):1575-89. PubMed ID: 11391689
    [Abstract] [Full Text] [Related]

  • 2. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A, Qaqish BF, Schell MJ.
    Biometrics; 2005 Jun 15; 61(2):540-5. PubMed ID: 16011702
    [Abstract] [Full Text] [Related]

  • 3. Exact permutational tests for group sequential clinical trials.
    Mehta CR, Patel N, Senchaudhuri P, Tsiatis A.
    Biometrics; 1994 Dec 15; 50(4):1042-53. PubMed ID: 7786986
    [Abstract] [Full Text] [Related]

  • 4. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y, Grambsch PM, Neaton JD.
    Clin Trials; 2007 Dec 15; 4(2):140-53. PubMed ID: 17456513
    [Abstract] [Full Text] [Related]

  • 5. Early stopping rules in clinical trials based on sequential monitoring of serious adverse events.
    Kramar A, Bascoul-Mollevi C.
    Med Decis Making; 2009 Dec 15; 29(3):343-50. PubMed ID: 19073996
    [Abstract] [Full Text] [Related]

  • 6. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L, Woodworth G.
    Stat Med; 2009 Apr 30; 28(9):1339-52. PubMed ID: 19226557
    [Abstract] [Full Text] [Related]

  • 7. Construction of a continuous stopping boundary from an alpha spending function.
    Betensky RA.
    Biometrics; 1998 Sep 30; 54(3):1061-71. PubMed ID: 9750252
    [Abstract] [Full Text] [Related]

  • 8. Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials.
    Sébille V, Bellissant E.
    Fundam Clin Pharmacol; 2005 Oct 30; 19(5):569-78. PubMed ID: 16176336
    [Abstract] [Full Text] [Related]

  • 9. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR, Shahumyan H.
    Stat Med; 2007 Nov 30; 26(27):4939-57. PubMed ID: 17582801
    [Abstract] [Full Text] [Related]

  • 10. Over-ruling a group sequential boundary--a stopping rule versus a guideline.
    Lan KK, Lachin JM, Bautista O.
    Stat Med; 2003 Nov 15; 22(21):3347-55. PubMed ID: 14566919
    [Abstract] [Full Text] [Related]

  • 11. An algorithm for the design of group sequential triangular tests for single-arm clinical trials with a binary endpoint.
    McWilliams TP.
    Stat Med; 2010 Nov 30; 29(27):2794-801. PubMed ID: 20860065
    [Abstract] [Full Text] [Related]

  • 12. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM.
    Stat Med; 2006 Oct 15; 25(19):3348-65. PubMed ID: 16345019
    [Abstract] [Full Text] [Related]

  • 13. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR, Petroni GR.
    Biometrics; 1996 Dec 15; 52(4):1375-86. PubMed ID: 8962459
    [Abstract] [Full Text] [Related]

  • 14. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
    Brutti P, Gubbiotti S, Sambucini V.
    Stat Med; 2011 Jun 30; 30(14):1648-64. PubMed ID: 21520453
    [Abstract] [Full Text] [Related]

  • 15. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE, Cook JD.
    Clin Trials; 2009 Jun 30; 6(3):217-26. PubMed ID: 19528131
    [Abstract] [Full Text] [Related]

  • 16. Phase II multi-step planning methods in oncology: comparison, recommendations and potential applications.
    Medioni J, de Rycke Y, Tournoux Facon C, Mallet A, Asselain B.
    Contemp Clin Trials; 2007 May 30; 28(3):249-57. PubMed ID: 17113357
    [Abstract] [Full Text] [Related]

  • 17. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K, Shan M.
    Contemp Clin Trials; 2008 Jan 30; 29(1):32-41. PubMed ID: 17544337
    [Abstract] [Full Text] [Related]

  • 18. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS, Kittelson JM, Gillen DL.
    Stat Med; 2007 Dec 10; 26(28):5047-80. PubMed ID: 17573678
    [Abstract] [Full Text] [Related]

  • 19. Stopping boundaries adjusted for sample size reestimation and negative stop.
    Shun Z.
    J Biopharm Stat; 2002 Nov 10; 12(4):485-502. PubMed ID: 12477071
    [Abstract] [Full Text] [Related]

  • 20. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B, Korn EL.
    Clin Trials; 2009 Apr 10; 6(2):119-25. PubMed ID: 19342463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.